Home › Breastfeeding › NCT05939700

Mavacamten Pregnancy Surveillance Program

Who can join

Ages 15 and older · Women

Inclusion Criteria:

* Exposure to at least 1 dose of mavacamten at any time during pregnancy (from 4 months prior to conception to pregnancy outcome) and/or at any time during breastfeeding (up to 12 months of infant age or weaning, whichever comes first)
* At least 15 years of age or older at the time of enrollment
* Informed consent or institutional review board/ethics committee-approved waiver of informed consent

Exclusion Criteria:

\- None

About the study

The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.

What is being tested

• Mavacamten (drug)

Sponsor: Bristol-Myers Squibb · Participants: 20 · Started: Nov 9, 2023

Contact the study team

• BMS Study Connect Contact Center www.BMSStudyConnect.com · Phone: 855-907-3286

Official record on ClinicalTrials.gov — NCT05939700

Locations in the U.S.

Conditions

• Breastfeeding
• Hypertrophic Cardiomyopathy

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.